Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) announced on October 6, 2025 that Sanjeev Narula will join the company as Chief Financial and Business Officer. The appointment was made to strengthen the company’s financial leadership as it pursues its strategy to achieve profitability in 2026 without additional equity financing.
Narula brings extensive experience from his most recent role as Chief Financial Officer at Intra‑Cellular Therapies, where he oversaw finance leading up to the company’s $14.6 billion acquisition by Johnson & Johnson. Prior to that, he served as CFO of Viatris and CFO of Upjohn, a former Pfizer division, and held senior finance positions at Pfizer’s Essential Health Business and Primary Care Business Unit. His background spans global commercial, R&D, IT, and supply functions, positioning him to support Phathom’s growth and cost‑control initiatives.
The new CFO is expected to play a critical role in executing Phathom’s plan to drive financial performance and unlock shareholder value as VOQUEZNA gains traction in the gastrointestinal market. His expertise in capital strategy, M&A, and financial planning will help the company navigate its path to profitability while managing the company’s cash position and operating expenses. This leadership change is a key component of Phathom’s broader strategic shift toward financial discipline and long‑term value creation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.